Driving CARs to BARs: The Road to Engineered Specific Human T Regulatory Cells

Immunology Interest Group David W. Scott, Ph.D. is Vice Chair for Research in the Department of Medicine at the Uniformed Services School of Health Sciences, Bethesda, MD. An alumnus of Antioch College, he received his M.S. degree from the University of Chicago and Ph.D. from Yale University in 1969. Following a post-doctoral fellowship at Oxford University, he has held tenured faculty positions at Duke University, the University of Rochester, and the University of Maryland Medical School. He assumed his current position in September 2010. Dr. Scott has contributed to over 200 research papers on several subjects on immunologic tolerance, and its application in autoimmune diseases, hemophilia and gene therapy. He is the author of two textbooks, including The Nature of Immunologic Tolerance, and recipient of a number of awards, e.g. Distinguished Service Award from the American Association of Immunologists, a Boarhaave Professorship at Leiden University in Holland, and the 2009 Scientific Achievement Award from AAPS. Abstract: Clinical application of expanded T regulatory cells (Tregs) offers great promise for the treatment of undesirable immune responses. However, treatment with polyclonal Tregs, which are not specific for a single epitope, could potentially lead to global immunosuppression. We have engineered human T cells to express chimeric antigen receptors (CARs) using either T-cell receptors from MS or hemophilia patients or specific single chain Fv’s. Thus, we ada...
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video